Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer

Introduction: Chemoradiation based on cisplatin is the standard treatment of locally advanced cervical cancer, however, a subset of patients are either elderly and/or have comorbidities such as diabetes and hypertension. These conditions may compromise the administration of cisplatin. We report our Institution experience with weekly carboplatin as a radiosensitizer for the management of this subset of patients. Patients and methods: We reviewed the files of 59 patients with locally advanced cervical cancer who were treated with primary chemoradiation with weekly carboplatin. Response rate, toxicity and survival were analyzed. Results: Mean age was 62 years (range, 36-83 years). The majority of cases were squamous cell carcinoma (88.14%), and distribution according to FIGO Stage was IB2 8.4%, IIA 13.5%, IIB 52.5%, IIIA 3.3% and IIIB 18.6%; Overall, 100% and 91% of patients completed external beam and intracavitary therapy. Seventy-nine percent received from five to six planned cycles of weekly carboplatin. Complete responses were achieved in 49 (83.05 %) patients, whereas ten patients (16.95%) had either persistent or progressive disease. The most common toxicities were grades 1 and 2 hematological and gastrointestinal. At median follow-up (20 months; range 2-48 months), 16 patients (32.65%) have relapsed. Estimated 30-month overall survival is 63%. Conclusions: Weekly carboplatin concurrent with pelvic radiation is well tolerated in patients with locally advanced carcinoma of the cervix who are older than 70 years and/or have diabetes mellitus and/or high blood pressure, however, the apparently slighty lower survival observed cautions against its routine use.

Chemoradiation; Cervical cancer; Carboplatin

[1] Mohar A., Frias-Mendivil M.: “Epidemiology of cervical cancer”. Cancer Invest., 2000, 18, 584.

[2]Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P. et al.: “Randomized study of radical surgery versus radiotherapy for Stage Ib-IIa cervical cancer”. Lancet, 1997, 350, 535.

[3] Green J.A., Kirwan J.M., Tierney J.F., Symonds P., Fresco L., Collingwood M. et al.: “Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis”. Lancet, 2001, 358, 781.

[4] Rose P.G., Ali S., Watkins E., Thigpen J.T., Deppe G., Clarke- Pearson D.L. et al.: “Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin or cisplatin-based combination chemotherapy or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A Gynecologic Oncology Group Study”. J. Clin. Oncol., 2007, 25, 2804.

[5] Brenner B.M., Meyer T.W., Hostetter T.H.: “Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease”. N. Engl. J. Med., 1982, 307, 652.

[6] Tumer N., Scarpace P.J., Lowenthal D.T.: “Geriatric pharmacology: basic and clinical considerations”. Annu. Rev. Pharmacol. Toxicol., 1992, 32, 271.

[7] King H., Aubert R.E., Herman W.H.: “Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections”. Diabetes Care, 1998, 121, 1414.

[8] Mensah G.A.: “The global burden of hypertension: good news and bad news”. Cardiol. Clin., 2002, 20, 181.

[9] American Diabetes Association: “Diabetic Nephropathy (Position Statement)”. Diabetes Care, 2002, 25 (suppl. 1), S85.

[10] Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch. Intern. Med., 1997, 157, 2413.

[11] Muggia F.M.: “Overview of carboplatin: replacing complementing and extending the therapeutics horizons of cisplatin”. Semin. Oncol., 1989, 16 (suppl. 5), 7.

[12] Go R.S., Adjei A.A.: “Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin”. J. Clin. Oncol., 1999, 17, 409.

[13] Monk B.J., Alberts D.S., Burger R.A., Burger R.A., Fanta P.T., Hallum A.V. 3rd et al.: “In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers”. Gynecol. Oncol., 1998, 71, 308.

[14] Weiss G.R., Green S., Hannigan E.V., Boutselis J.G., Surwit E.A., Wallace D.L. et al.: “A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study”. Gynecol. Oncol., 1990, 39, 332.

[15] Arseneau J., Blessing J.A., Stehman F.B., McGehee R. et al.: “Phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study)”. Invest. New Drugs., 1986, 4, 187.

[16] Noda K., Kato T., Ikeda M., Akiya K., Yajima A., Ueda G. et al.: “Phase II study of carboplatin in cervical carcinoma”. Gan To Kagaku Ryoho, 1988, 15, 3067.

[17] Lira-Puerto V., Silva A., Morris M., Martinez R., Groshen S., Morales-Canfield F. et al.: “Phase II trial of carboplatin or iproplatin in cervical cancer”. Cancer Chemother. Pharmacol., 1991, 28, 391.

[18] McGuire W.P. 3rd, Arseneau J., Blessing J.A., DiSaia P.J., Hatch K.D., Given F.T. Jr. et al.: “A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study”. J. Clin. Oncol., 1989, 7, 1462.

[19] Schwachofer J.H., Crooijmans R.P., Hoogenhout J.: “Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: influence of treatment sequence”. Int. J. Radiat. Oncol. Biol. Phys., 1991, 20, 1235.

[20] Yang L.X., Douple E.B., Wang H.J.: “Irradiation enhances cellular uptake of carboplatin”. Int. J. Radiat. Oncol. Biol. Phys., 1995, 33, 641.

[21] Duenas-Gonzalez A., Cetina L., Sánchez B., Gomez E., Rivera L., Hinojosa J. et al.: “A phase I study of carboplatin concurrent with radiation in FIGO Stage IIIB cervix uteri carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 2002, 56, 1361.

[25] Mayersohn M.: “Pharmacokinetics in the elderly”. Environ Health Perspect., 1994, 102 (suppl. 11), 119.

[26] Lichtman S.M., Villani G.: “Chemotherapy in the elderly: pharmacologic considerations”. Cancer Control, 2000, 7, 548.

[27] Janssen-Heijnen M.L., Schipper R.M., Razenberg P.P., Crommelin M.A., Coebergh J.W.: “Prevalence of comorbidity in lung cancer patients and its relationship with treatment: a population - based study”. Lung Cancer, 1998, 21, 105.

[28] Micheletti E., La Face B., Bianchi E., Cagna E., Apostoli P., Ruggeri G. et al.: “Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIIB (UICC). A phase I/II and pharmacokinetic study”. Am. J. Clin. Oncol., 1997, 20, 613.

[29] Muderspach L.I., Curtin J.P., Roman L.D., Gebhardt J.A., Klement V., Quian D. et al.: “Carboplatin as a radiation sensitizer in locally advanced cervical cancer: a pilot study”. Gynecol. Oncol., 1997, 65, 336.

[30] Higgins R.V., Naumann W.R., Hall J.B., Haake M.: “Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer”. Gynecol. Oncol., 2003, 89, 499.

[31] Dubay R.A., Rose P.G., O’Malley D.M., Shalodi A.D., Ludin A.: “Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer”. Gynecol. Oncol., 2004, 94, 121.

[32] Cetina L., Rivera L., Hinojosa J., Poitevin A., Uribe J., Lopez-Graniel C. et al.: “Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results”. BMC Women’s Health, 2006, 6, 3.

[33] Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E. et al.: “Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer”. New Engl. J. Med., 1999, 340, 1137.

[34] Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L. et al.: “A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky Stage IB cervical carcinoma: a randomized trial of the Gynecology Oncology Group”. New Engl. J. Med., 1999, 340, 1154.

[35] Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler W.C. Jr. et al.: “A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in Stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group Study”. J. Clin. Oncol., 1999, 17, 1339.

[36] Brooks S.E., Chen T.T., Ghosh A., Mullins C.D., Gardner J.F., Baquet R.T.: “Cervical cancer outcomes analysis: impact of age, race, and comorbid illness on hospitalizations for invasive carcinoma of the cervix”. Gynecol. Oncol., 2000, 79, 107.

[37] Mitchell P.A., Waggoner S., Rotmensch J., Mundt A.J.: “Cervical cancer in the elderly treated with radiation therapy”. Gynecol. Oncol., 1998, 71, 291.

[38] Peipert J.F., Wells C.K., Schwartz P.E., Feinstein A.R.: “The impact of symptoms and comorbidity on prognosis in Stage IB cervical cancer”. Am. J. Obstet. Gynecol., 1993, 169, 598.

[39] Goldstein R.S., Mayor G.H., Rosenbaum R.W., Hook J.B., Santiago J.V., Bond J.T.: “Glucose intolerance following cis-platinum treatment in rats”. Toxicology, 1982, 24, 273.

[40] Komdeur R., Derksen J., Legdeur M.C., Hylkema B.S.: “Cisplatin- induced hyperglycemic hyperosmolar coma”. Neth J. Med., 2007, 65, 36.

[41] Sakakura C., Hagiwara A., Kin S., Yamamoto K., Okamoto K., Yamaguchi T. et al.: “A case of hyperosmolar nonketotic coma occurring during chemotherapy using cisplatin for gallbladder cancer”. Hepatogastroenterology, 1999, 46, 2801.

[42] Lin A., Jabbari S., Worden F.P., Bradford C.R., Chepeha D.B., Teknos T.N. et al.: “Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2005, 63, 1413.

[43] Pietilä S., Ala-Houhala M., Lenko H.L., Harmoinen A.P., Turjanmaa V., Mäkipernaa A.: “Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment”. Pediatr. Blood Cancer, 2005, 44, 363.

[44] Scott L.A., Madan E., Valentovic M.A.: “Attenuation of cisplatin nephrotoxicity by streptozotocin-induced diabetes”. Fundam Appl. Toxicol., 1989, 12, 530.

[45] Costa G.J., Fernandes A.L., Pereira J.R., Curtis J.R., Santoro I.L.: “Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC)”. Lung Cancer, 2006, 53, 171.

[46] Chitapanarux I., Lorvidhaya V., Kamnerdsupaphon P., Sumitsawan Y., Tharavichitkul E., Sukthomya V., Ford J.: “Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial”. Eur. J. Cancer, 2007, 43, 1399.